Literature DB >> 11772976

Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver.

A L Gerbes1, V Gülberg, M Bilzer, M Vogeser.   

Abstract

BACKGROUND AND AIMS: Diagnosis of moderately impaired renal function is of particular importance in patients with cirrhosis of the liver. Whereas patients with a markedly impaired glomerular filtration rate can be diagnosed easily by elevated serum creatinine concentrations, moderately reduced renal function may be missed by this conventional parameter. Recently, cystatin C has been suggested as a sensitive marker of renal function, independent of sex or muscle mass. Therefore, the aim of this study was to investigate the value of serum cystatin C concentration for the detection of moderately impaired renal function.
METHODS: Ninety seven in-hospital patients with cirrhosis and a 24 hour creatinine clearance of at least 40 ml/min were investigated and divided into group 1 (creatinine clearance > or = 70 ml/min; n = 55) and group 2 (creatinine clearance 40-69 ml/min; n = 42).
RESULTS: Serum cystatin C concentrations (mean (SD): 1.31 (0.51) v 1.04 (0.34) mg/l (p = 0.008)) and creatinine concentrations (1.03 (0.52) v 0.86 (0.22) mg/100 ml (p=0.03)) were higher in group 2 than in group 1; there was no significant difference in urea concentrations. Receiver-operator characteristics (ROC) revealed a differential diagnostic advantage of cystatin C over creatinine and urea. At cut off concentrations of 1.0 mg/l, 0.9 mg/100 ml, and 28 mg/100 ml, respectively, cystatin C, creatinine, and urea exhibited 69%, 45%, and 44% sensitivity (p<0.05). As patients with a small muscle mass or reduced physical activity could be particularly prone to overestimation of their renal function, separate analyses were performed for the subgroups of female and Child-Pugh class C patients, respectively. In both groups, discrimination between patients with moderately impaired and normal renal function was best with cystatin C. In female patients, sensitivity of cystatin C (77.8%) was superior (p<0.05) to that of creatinine (38.9%) and urea (41.2%). In Child-Pugh C patients, the ROC curve was significantly better for cystatin C than for creatinine.
CONCLUSIONS: Serum cystatin C determination could be a valuable tool in patients with cirrhosis, particularly with Child-Pugh class C or in female patients, for early diagnosis of moderately impaired renal function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772976      PMCID: PMC1773066          DOI: 10.1136/gut.50.1.106

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis.

Authors:  R P Woitas; B Stoffel-Wagner; S Flommersfeld; U Poege; P Schiedermaier; H U Klehr; U Spengler; F Bidlingmaier; T Sauerbruch
Journal:  Clin Chem       Date:  2000-05       Impact factor: 8.327

2.  Serum cystatin C as a marker of the renal function.

Authors:  E Randers; J H Kristensen; E J Erlandsen; H Danielsen
Journal:  Scand J Clin Lab Invest       Date:  1998-11       Impact factor: 1.713

3.  Rapid evaluation of creatinine clearance.

Authors:  J Kampmann; K Siersbaek-Nielsen; M Kristensen; J M Hansen
Journal:  Acta Med Scand       Date:  1974-12

4.  Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study.

Authors:  M A Papadakis; A I Arieff
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

5.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

6.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

7.  Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites.

Authors:  A L Gerbes; V Gülberg; T Waggershauser; J Holl; M Reiser
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

8.  Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis.

Authors:  R Orlando; M Floreani; R Padrini; P Palatini
Journal:  Clin Nephrol       Date:  1999-06       Impact factor: 0.975

Review 9.  Medical treatment of ascites in cirrhosis.

Authors:  A L Gerbes
Journal:  J Hepatol       Date:  1993       Impact factor: 25.083

Review 10.  Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

Authors:  R W Schrier; V Arroyo; M Bernardi; M Epstein; J H Henriksen; J Rodés
Journal:  Hepatology       Date:  1988 Sep-Oct       Impact factor: 17.425

View more
  40 in total

Review 1.  Commentary: clinical diagnostic use of cystatin C.

Authors:  Davis Massey
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

Review 2.  Kidney Failure and Liver Allocation: Current Practices and Potential Improvements.

Authors:  Varun Saxena; Jennifer C Lai
Journal:  Adv Chronic Kidney Dis       Date:  2015-09       Impact factor: 3.620

3.  Gender disparity in liver transplant waiting-list mortality: the importance of kidney function.

Authors:  Ayse L Mindikoglu; Arie Regev; Stephen L Seliger; Laurence S Magder
Journal:  Liver Transpl       Date:  2010-10       Impact factor: 5.799

4.  Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure.

Authors:  Zhi-Hong Wan; Jian-Jun Wang; Shao-Li You; Hong-Ling Liu; Bing Zhu; Hong Zang; Chen Li; Jing Chen; Shao-Jie Xin
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

5.  Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis.

Authors:  Mohammed A Sharawey; Eglal M Shawky; Lamia H Ali; Ahmed Ali Mohammed; Hatem A Hassan; Yasser M Fouad
Journal:  Hepatol Int       Date:  2011-03-12       Impact factor: 6.047

Review 6.  Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction.

Authors:  Louise Madeleine Risør; Flemming Bendtsen; Søren Møller
Journal:  Hepatol Int       Date:  2014-09-27       Impact factor: 6.047

Review 7.  Management of hepatorenal syndrome.

Authors:  Halit Ziya Dundar; Tuncay Yılmazlar
Journal:  World J Nephrol       Date:  2015-05-06

8.  Assessing glomerular filtration rate in hospitalized patients: a comparison between CKD-EPI and four cystatin C-based equations.

Authors:  Alfonso Segarra; Judith de la Torre; Natalia Ramos; Augusto Quiroz; Maria Garjau; Irina Torres; M Antonia Azancot; Montserrat López; Ana Sobrado
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 8.237

Review 9.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

10.  Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Authors:  Ayse L Mindikoglu; Antone R Opekun; William E Mitch; Laurence S Magder; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; Charles D Howell; Jean-Pierre Raufman; Abbas Rana; John A Goss; Saira A Khaderi; John M Vierling
Journal:  Dig Dis Sci       Date:  2018-02-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.